Your browser doesn't support javascript.
loading
The Immunology of DLBCL.
Takahara, Taishi; Nakamura, Shigeo; Tsuzuki, Toyonori; Satou, Akira.
Affiliation
  • Takahara T; Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute 480-1195, Japan.
  • Nakamura S; Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya 466-8550, Japan.
  • Tsuzuki T; Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute 480-1195, Japan.
  • Satou A; Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute 480-1195, Japan.
Cancers (Basel) ; 15(3)2023 Jan 29.
Article in En | MEDLINE | ID: mdl-36765793
ABSTRACT
Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy and is the most common type of malignant lymphoid neoplasm. While some DLBCLs exhibit strong cell-autonomous survival and proliferation activity, others depend on interactions with non-malignant cells for their survival and proliferation. Recent next-generation sequencing studies have linked these interactions with the molecular classification of DLBCL. For example, germinal center B-cell-like DLBCL tends to show strong associations with follicular T cells and epigenetic regulation of immune recognition molecules, whereas activated B-cell-like DLBCL shows frequent genetic aberrations affecting the class I major histocompatibility complex. Single-cell technologies have also provided detailed information about cell-cell interactions and the cell composition of the microenvironment of DLBCL. Aging-related immunological deterioration, i.e., immunosenescence, also plays an important role in DLBCL pathogenesis, especially in Epstein-Barr virus-positive DLBCL. Moreover, DLBCL in "immune-privileged sites"-where multiple immune-modulating mechanisms exist-shows unique biological features, including frequent down-regulation of immune recognition molecules and an immune-tolerogenic tumor microenvironment. These advances in understanding the immunology of DLBCL may contribute to the development of novel therapies targeting immune systems.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2023 Document type: Article Affiliation country: Japan Publication country: CH / SUIZA / SUÍÇA / SWITZERLAND

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2023 Document type: Article Affiliation country: Japan Publication country: CH / SUIZA / SUÍÇA / SWITZERLAND